HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma.

Yanbin Wang,Jianing Yan,Zhaoqiang Jiang,Shibo Ying

doi:10.1155/2019/4183157

Yanbin Wang, Jianing Yan + Show 2 more

Open Access

https://doi.org/10.1155/2019/4183157

Copy DOI

Abstract

Malignant mesothelioma (MM) is a rare, aggressive, and highly lethal cancer that is substantially induced by exposure to asbestos fibers. High-mobility group box 1 (HMGB1) is an intriguing proinflammatory molecule involved in MM. In this review, we describe the possible crucial roles of HMGB1 in carcinogenic mechanisms based on in vivo and in vitro experimental evidence and outline the clinical findings of epidemiological investigations regarding the possible roles of HMGB1 as a biomarker for MM. We conclude that novel strategies targeting HMGB1 may suppress MM cells and interfere with asbestos-induced inflammation.

Highlights

Malignant mesothelioma (MM), which originates from the mesothelial cells that form the lining of the viscera, is a rare, aggressive, and highly lethal cancer
No significant differences in High-mobility group box 1 (HMGB1) levels were observed between the two groups with different exposure durations (AE < 10 and AE ≥ 10 years) AE [59]. These results suggest that one possible mechanism for asbestos-induced chronic inflammation is the secretion of HMGB1 into the stroma, after which it appears in the systemic circulation, regardless of asbestos exposure duration
Findings to date provide new insight into the molecular mechanisms underlying the progression and prognosis of MM and may lead to new approaches for the effective diagnosis and therapy of MM

Summary

Introduction

Malignant mesothelioma (MM), which originates from the mesothelial cells that form the lining of the viscera, is a rare, aggressive, and highly lethal cancer. HMGB1 can interact with cell surface receptors, such as the receptor for advanced glycation end products (RAGE), the toll-like family of receptors, and chemokine receptor-4, to induce their corresponding signaling pathways. These responses eventually lead to the activation of NF-κB and the induction of activator protein 1 and mitogen-activated protein kinase pathways, which are strongly associated with triggering inflammation [32,33,34]. Because increasing evidence strongly suggests that HMGB1 is involved in MM and functions as a potential multiple biomarker or curative target, HMGB1 in MM has been a hot research topic in recent years

Crucial Roles of HMGB1 in the Carcinogenic Mechanism in MM

Possible Roles of HMGB1 as a Biomarker for MM

HMGB1-Targeting Therapeutic Strategies

Findings

Conclusion and Future Perspectives